vs

Side-by-side financial comparison of CALAVO GROWERS INC (CVGW) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

CALAVO GROWERS INC is the larger business by last-quarter revenue ($124.7M vs $75.5M, roughly 1.7× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -26.6%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $1.2M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -1.2%).

Calavo Growers, Inc. is an international consumer goods and farm products company. It packages, and distributes avocados and other fruits, as well as their fresh prepared food to restaurants, stores, and individual customers worldwide.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CVGW vs PBYI — Head-to-Head

Bigger by revenue
CVGW
CVGW
1.7× larger
CVGW
$124.7M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+54.4% gap
PBYI
27.7%
-26.6%
CVGW
More free cash flow
PBYI
PBYI
$13.2M more FCF
PBYI
$14.4M
$1.2M
CVGW
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-1.2%
CVGW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVGW
CVGW
PBYI
PBYI
Revenue
$124.7M
$75.5M
Net Profit
$3.8M
Gross Margin
9.3%
69.3%
Operating Margin
-1.4%
22.7%
Net Margin
3.1%
Revenue YoY
-26.6%
27.7%
Net Profit YoY
2846.0%
EPS (diluted)
$0.22
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVGW
CVGW
PBYI
PBYI
Q4 25
$124.7M
$75.5M
Q3 25
$178.8M
$54.5M
Q2 25
$190.5M
$52.4M
Q1 25
$154.4M
$46.0M
Q4 24
$170.0M
$59.1M
Q3 24
$179.6M
$80.5M
Q2 24
$184.4M
$47.1M
Q1 24
$127.6M
$43.8M
Net Profit
CVGW
CVGW
PBYI
PBYI
Q4 25
$3.8M
Q3 25
$4.7M
$8.8M
Q2 25
$6.8M
$5.9M
Q1 25
$4.4M
$3.0M
Q4 24
$-139.0K
Q3 24
$-732.0K
$20.3M
Q2 24
$6.1M
$-4.5M
Q1 24
$-6.3M
$-4.8M
Gross Margin
CVGW
CVGW
PBYI
PBYI
Q4 25
9.3%
69.3%
Q3 25
10.2%
77.7%
Q2 25
9.5%
76.5%
Q1 25
10.2%
77.1%
Q4 24
9.7%
76.4%
Q3 24
11.2%
63.9%
Q2 24
11.1%
77.4%
Q1 24
8.4%
75.5%
Operating Margin
CVGW
CVGW
PBYI
PBYI
Q4 25
-1.4%
22.7%
Q3 25
4.8%
17.6%
Q2 25
4.0%
12.7%
Q1 25
3.3%
8.7%
Q4 24
1.8%
22.6%
Q3 24
5.2%
27.4%
Q2 24
4.0%
-4.6%
Q1 24
-2.4%
-5.3%
Net Margin
CVGW
CVGW
PBYI
PBYI
Q4 25
3.1%
Q3 25
2.6%
16.2%
Q2 25
3.6%
11.2%
Q1 25
2.9%
6.5%
Q4 24
-0.1%
Q3 24
-0.4%
25.2%
Q2 24
3.3%
-9.6%
Q1 24
-4.9%
-11.0%
EPS (diluted)
CVGW
CVGW
PBYI
PBYI
Q4 25
$0.22
$0.26
Q3 25
$0.26
$0.17
Q2 25
$0.38
$0.12
Q1 25
$0.25
$0.06
Q4 24
$-0.01
$0.40
Q3 24
$-0.04
$0.41
Q2 24
$0.34
$-0.09
Q1 24
$-0.35
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVGW
CVGW
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$61.2M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$206.9M
$130.3M
Total Assets
$292.2M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVGW
CVGW
PBYI
PBYI
Q4 25
$61.2M
$97.5M
Q3 25
$63.8M
$94.4M
Q2 25
$60.4M
$96.0M
Q1 25
$48.5M
$93.2M
Q4 24
$57.0M
$101.0M
Q3 24
$1.1M
$96.7M
Q2 24
$4.3M
$96.8M
Q1 24
$5.7M
$107.2M
Total Debt
CVGW
CVGW
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
CVGW
CVGW
PBYI
PBYI
Q4 25
$206.9M
$130.3M
Q3 25
$206.4M
$115.3M
Q2 25
$206.6M
$104.7M
Q1 25
$202.9M
$97.1M
Q4 24
$200.3M
$92.1M
Q3 24
$205.2M
$71.1M
Q2 24
$207.3M
$48.5M
Q1 24
$202.5M
$51.0M
Total Assets
CVGW
CVGW
PBYI
PBYI
Q4 25
$292.2M
$216.3M
Q3 25
$301.2M
$202.9M
Q2 25
$321.5M
$194.9M
Q1 25
$298.9M
$196.2M
Q4 24
$301.1M
$213.3M
Q3 24
$382.4M
$220.7M
Q2 24
$411.4M
$205.0M
Q1 24
$394.7M
$214.1M
Debt / Equity
CVGW
CVGW
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVGW
CVGW
PBYI
PBYI
Operating Cash FlowLast quarter
$2.3M
$14.4M
Free Cash FlowOCF − Capex
$1.2M
$14.4M
FCF MarginFCF / Revenue
1.0%
19.1%
Capex IntensityCapex / Revenue
0.9%
0.0%
Cash ConversionOCF / Net Profit
0.60×
TTM Free Cash FlowTrailing 4 quarters
$19.4M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVGW
CVGW
PBYI
PBYI
Q4 25
$2.3M
$14.4M
Q3 25
$8.0M
$9.7M
Q2 25
$15.7M
$14.1M
Q1 25
$-4.4M
$3.6M
Q4 24
$10.8M
$15.6M
Q3 24
$11.4M
$11.0M
Q2 24
$2.1M
$1.0M
Q1 24
$58.0K
$11.2M
Free Cash Flow
CVGW
CVGW
PBYI
PBYI
Q4 25
$1.2M
$14.4M
Q3 25
$7.3M
$9.7M
Q2 25
$15.6M
$14.1M
Q1 25
$-4.7M
$3.6M
Q4 24
$10.5M
$15.6M
Q3 24
$11.3M
$11.0M
Q2 24
$745.0K
$1.0M
Q1 24
$-972.0K
FCF Margin
CVGW
CVGW
PBYI
PBYI
Q4 25
1.0%
19.1%
Q3 25
4.1%
17.7%
Q2 25
8.2%
26.8%
Q1 25
-3.1%
7.7%
Q4 24
6.2%
26.4%
Q3 24
6.3%
13.7%
Q2 24
0.4%
2.1%
Q1 24
-0.8%
Capex Intensity
CVGW
CVGW
PBYI
PBYI
Q4 25
0.9%
0.0%
Q3 25
0.4%
0.0%
Q2 25
0.1%
0.0%
Q1 25
0.2%
0.1%
Q4 24
0.2%
0.0%
Q3 24
0.1%
0.0%
Q2 24
0.7%
0.0%
Q1 24
0.8%
0.0%
Cash Conversion
CVGW
CVGW
PBYI
PBYI
Q4 25
0.60×
Q3 25
1.69×
1.10×
Q2 25
2.29×
2.41×
Q1 25
-1.00×
1.21×
Q4 24
Q3 24
0.54×
Q2 24
0.35×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVGW
CVGW

Fresh Products$104.7M84%
Segment Prepared$14.5M12%
Tomatoes$4.6M4%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons